NEDD9 depletion leads to MMP14inactivation by TIMP2 and prevents invasion and metastasis

Molecular Cancer Research

Volumn 12, Issue 1, 2014, Pages 69-81

  McLaughlin, Sarah L ^a   Ice, Ryan J ^a   Rajulapati, Anuradha ^a   Kozyulina, Polina Y ^a   Livengood, Ryan H ^a   Kozyreva, Varvara K ^a   Loskutov, Yuriy V ^a   Culp, Mark V ^a   Weed, Scott A ^a   Ivanov, Alexey V ^a   Pugacheva, Elena N ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCKING PROTEIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; NEDD9 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER TISSUE; CELL INVASION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; ENZYME INACTIVATION; FEMALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BREAST NEOPLASMS; CARCINOMA IN SITU; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MCF-7 CELLS; MICE; MICE, INBRED NOD; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASTIC CELLS, CIRCULATING; PHOSPHOPROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSPLANTATION, HETEROLOGOUS;

EID: 84893087890     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0300     Document Type: Article

References (40)

1. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006;125:1269-81.
2. Kondo S, Iwata S, Yamada T, Inoue Y, Ichihara H, Kichikawa Y, et al. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer. Clin Cancer Res 2012;18:6326-38.
3. Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 2006;25:1721-32.
4. Ahn J, Sanz-Moreno V, Marshall CJ. The metastasis gene NEDD9 product acts through integrin beta3 and Src to promote mesenchymal motility and inhibit amoeboid motility. J Cell Sci 2012;125: 1814-26.
5. Fashena SJ, Einarson MB, O'Neill GM, Patriotis C, Golemis EA. Dissection of HEF1-dependent functions in motility and transcriptional regulation. J Cell Sci 2002;115:99-111.
6. Guerrero MS, Parsons JT, Bouton AH. Cas and NEDD9 contribute to tumor progression through dynamic regulation of the cytoskeleton. Genes Cancer 2012;3:371-81.
7. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008;135:510-23.
8. Kong C, Wang C, Wang L, Ma M, Niu C, Sun X, et al. NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS ONE 2011;6:e22666.
9. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
10. Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MMP14 trafficking to invadopodia. J Cell Sci 2009;122: 3015-24.
11. Osenkowski P, Toth M, Fridman R. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MMP14). J Cell Physiol 2004;200:2-10.
12. Yana I, Weiss SJ. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 2000;11: 2387-401.
13. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2.FEBS Lett 1996;393:101-4.
14. Shofuda K, Moriyama K, Nishihashi A, Higashi S, Mizushima H, Yasumitsu H, et al. Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. J Biochem 1998;124:462-70.
15. Hernandez-Barrantes S, Toth M, Bernardo MM, Yurkova M, Gervasi DC, Raz Y, et al. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MMP14) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MMP14 processing and pro-MMP-2 activation. J Biol Chem 2000;275:12080-9.
16. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 2006;66:3034-43.
17. Ayala I, Baldassarre M, Giacchetti G, Caldieri G, Tete S, Luini A, et al. Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. J Cell Sci 2008; 121:369-78.
18. Bowden ET, Onikoyi E, Slack R, Myoui A, Yoneda T, Yamada KM, et al. Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells. Exp Cell Res 2006;312: 1240-53.
19. Nyalendo C, Beaulieu E, Sartelet H, Michaud M, Fontaine N, Gingras D, et al. Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis 2008;29:1655-64.
20. Wu X, Gan B, Yoo Y, Guan JL. FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MMP14 and promotes ECM degradation. Dev Cell 2005;9:185-96.
21. Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, Serebriiskii IG, et al. NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res 2009;69:7198-206.
22. Little JL, Serzhanova V, Izumchenko E, Egleston BL, Parise E, Klein-Szanto AJ, et al. A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice. Oncogene 2013 Jan [Epub ahead of print]
23. Lucas JT Jr, Salimath BP, Slomiany MG, Rosenzweig SA. Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene 2010;29:4449-59.
24. Brabek J, Constancio SS, Siesser PF, Shin NY, Pozzi A, Hanks SK. Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells. Mol Cancer Res 2005;3:307-15.
25. Wang Y, McNiven MA. Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol 2012;196:375-85.
26. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 2007;129:1351-63.
27. Zinn KR, Chaudhuri TR, Szafran AA, O'Quinn D, Weaver C, Dugger K, et al. Noninvasive bioluminescence imaging in small animals. ILAR J 2008;49:103-15.
28. Jedeszko C, Sameni M, Olive MB, Moin K, Sloane BF. Visualizing protease activity in living cells: from two dimensions to four dimensions. Curr Protoc Cell Biol 2008;Chapter 4: Unit 7
29. Ice RJ, McLaughlin SM, Culp MV, Eddy ER, Livengood RH, Ivanov AV, et al. NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors. Cancer Res 2013;73:3168-80.
30. Pugacheva EN, Golemis EA. The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol 2005;7:937-46.
31. Madsen MW, Briand P. Relationship between tumorigenicity, in vitro invasiveness, and plasminogen activator production of human breast cell lines. Eur J Cancer 1990;26:793-7.
32. Ratnikov BI, Deryugina EI, Strongin AY. Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab Invest 2002;82:1583-90.
33. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, et al. MMP14expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002;16:555-64.
34. Li XY, Ota I, Yana I, Sabeh F, Weiss SJ. Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase. Mol Biol Cell 2008;19:3221-33.
35. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270:5331-8.
36. Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, et al. Crystal structure of the complex formed by themembrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 1998;17: 5238-48.
37. O'Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res 2007;67:8975-9.
38. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochimica Biophysica Acta 2010;1803:55-71.
39. Zhang M, Liu Y, Feng H, Bian X, Zhao W, Yang Z, et al. CD133 affects the invasive ability of HCT116 cells by regulating TIMP-2. Am J Pathol 2013;182:565-76.
40. Remacle A, Murphy G, Roghi C. Membrane type I-matrix metalloproteinase (MMP14) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci 2003;116:3905-16.